Correlation of telomere length shortening with TP53 somatic mutations, polymorphisms and allelic loss in breast tumors and esophageal cancer

Oncology Reports

Volumn 29, Issue 1, 2013, Pages 226-236

  Hao, Xiao Dan ^a,b   Yang, Yue ^a   Song, Xin ^a,d   Zhao, Xue Ke ^b,h   Wang, Li Dong ^c   He, Jun Dong ^f,g   Kong, Qing Peng ^d,j   Tang, Nelson Leung Sang ^e,f   Zhang, Ya Ping ^a,b,d,i  

^a KUNMING INSTITUTE OF ZOOLOGY   (China)

^b YUNNAN UNIVERSITY   (China)

^c UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^d KIZ/CUHK Joint Laboratory of Bioresources and Molecular Research in Common Diseases   (China)

^e First People's Hospital of Kunming   (China)

^f THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^g KUNMING MEDICAL UNIVERSITY   (China)

^h and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

ⁱ CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^j UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

more..

Author keywords

Allelic loss; Breast tumor; Esophageal cancer; Telomere erosion; TP53 variations

Indexed keywords

ADULT; AGED; ALLELE; ALLELIC LOSS; ARTICLE; BREAST TUMOR; CHROMOSOMAL INSTABILITY; CONTROLLED STUDY; CORRELATION ANALYSIS; ESOPHAGUS CANCER; FEMALE; GENE DELETION; GENE SEQUENCE; GENOTYPE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; TELOMERE SHORTENING; TP53 GENE; TUMOR SUPPRESSOR GENE; UNINDEXED SEQUENCE; WILD TYPE;

BREAST NEOPLASMS; ESOPHAGEAL NEOPLASMS; FEMALE; GENOMIC INSTABILITY; HUMANS; LOSS OF HETEROZYGOSITY; MUTATION; POLYMORPHISM, GENETIC; PROGNOSIS; TELOMERE; TELOMERE SHORTENING; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84872850915     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.2098     Document Type: Article

References (34)

1. Blackburn EH: Structure and function of telomeres. Nature 350: 569-573, 1991.
2. Hackett JA, Feldser DM and Greider CW: Telomere dysfunction increases mutation rate and genomic instability. Cell 106: 275-286, 2001.
3. Rudolph KL, Millard M, Bosenberg MW and DePinho RA: Telomere dysfunction and evolution of intestinal carcinoma in mice and humans. Nat Genet 28: 155-159, 2001.
4. Levy MZ, Allsopp RC, Futcher AB, Greider CW and Harley CB: Telomere end-replication problem and cell aging. J Mol Biol 225: 951-960, 1992.
5. Harley CB, Futcher AB and Greider CW: Telomeres shorten during ageing of human fibroblasts. Nature 345: 458-460, 1990.
6. von Figura G, Hartmann D, Song Z and Rudolph KL: Role of telomere dysfunction in aging and its detection by biomarkers. J Mol Med 87: 1165-1171, 2009.
7. Cosme-Blanco W, Shen MF, Lazar AJ, et al: Telomere dysfunction suppresses spontaneous tumorigenesis in vivo by initiating p53-dependent cellular senescence. EMBO Rep 8: 497-503, 2007.
8. Thanasoula M, Escandell JM, Martinez P, et al: p53 prevents entry into mitosis with uncapped telomeres. Curr Biol 20: 521-526, 2010.
9. Brassat U, Balabanov S, Bali D, et al: Functional p53 is required for effective execution of telomerase inhibition in BCR-ABL-positive CML cells. Exp Hematol 39: 66-76. e1-2, 2011.
10. Artandi SE and DePinho RA: Telomeres and telomerase in cancer. Carcinogenesis 31: 9-18, 2009.
11. Petitjean A, Mathe E, Kato S, et al: Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 28: 622-629, 2007.
12. Lasko D, Cavenee W and Nordenskjold M: Loss of constitutional heterozygosity in human cancer. Annu Rev Genet 25: 281-314, 1991.
13. Goh AM, Coffill CR and Lane DP: The role of mutant p53 in human cancer. J Pathol 223: 116-126, 2011.
14. Whibley C, Pharoah PD and Hollstein M: p53 polymorphisms: cancer implications. Nat Rev Cancer 9: 95-107, 2009.
15. Knudson AG Jr.: Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 68: 820-823, 1971.
16. Saeki H, Kitao H, Yoshinaga K, et al: Copy-neutral loss of heterozygosity at the p53 locus in carcinogenesis of esophageal squamous cell carcinomas associated with p53 mutations. Clin Cancer Res 17: 1731-1740, 2011.
17. Cawthon RM: Telomere measurement by quantitative PCR. Nucleic Acids Res 30: e47, 2002.
18. Gil ME and Coetzer TL: Real-time quantitative PCR of telomere length. Mol Biotechnol 27: 169-172, 2004.
19. Babizhayev MA, Savel'yeva EL, Moskvina SN and Yegorov YE: Telomere length is a biomarker of cumulative oxidative stress, biologic age, and an independent predictor of survival and therapeutic treatment requirement associated with smoking behavior. Am J Ther 18: e209-226, 2011.
20. Baird DM: Telomere dynamics in human cells. Biochimie 90: 116-121, 2008.
21. von Zglinicki T: Oxidative stress shortens telomeres. Trends Biochem Sci 27: 339-344, 2002.
22. Epel ES, Blackburn EH, Lin J, et al: Accelerated telomere shortening in response to life stress. Proc Natl Acad Sci USA 101: 17312-17315, 2004.
23. Artandi SE, Chang S, Lee SL, et al: Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice. Nature 406: 641-645, 2000.
24. Murnane JP: Telomeres and chromosome instability. DNA Repair 5: 1082-1092, 2006.
25. Chen M, Ye Y, Yang H, et al: Genome-wide profiling of chromosomal alterations in renal cell carcinoma using high-density single nucleotide polymorphism arrays. Int J Cancer 125: 2342-2348, 2009.
26. Greenblatt MS, Bennett WP, Hollstein M and Harris CC: Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54: 4855-4878, 1994.
27. Dumont P, Leu JI, Della Pietra AC III, George DL and Murphy M: The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33: 357-365, 2003.
28. Tabori U, Nanda S, Druker H, Lees J and Malkin D: Younger age of cancer initiation is associated with shorter telomere length in Li-Fraumeni syndrome. Cancer Res 67: 1415-1418, 2007.
29. Trkova M, Prochazkova K, Krutilkova V, Sumerauer D and Sedlacek Z: Telomere length in peripheral blood cells of germline TP53 mutation carriers is shorter than that of normal individuals of corresponding age. Cancer 110: 694-702, 2007.
30. Radpour R, Barekati Z, Haghighi MM, et al: Correlation of telomere length shortening with promoter methylation profile of p16/Rb and p53/p21 pathways in breast cancer. Mod Pathol 23: 763-772, 2010.
31. Pooley KA, Sandhu MS, Tyrer J, et al: Telomere length in prospective and retrospective cancer case-control studies. Cancer Res 70: 3170-3176, 2010.
32. Gramatges MM, Telli ML, Balise R and Ford JM: Longer relative telomere length in blood from women with sporadic and familial breast cancer compared with healthy controls. Cancer Epidemiol Biomarkers Prev 19: 605-613, 2010.
33. Zheng YL, Ambrosone C, Byrne C, Davis W, Nesline M and McCann SE: Telomere length in blood cells and breast cancer risk: investigations in two case-control studies. Breast Cancer Res Treat 120: 769-775, 2010.
34. Svenson U, Nordfjall K, Stegmayr B, et al: Breast cancer survival is associated with telomere length in peripheral blood cells. Cancer Res 68: 3618-3623, 2008.